Cargando…
Direct oral anticoagulants for unusual‐site venous thromboembolism
Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer dr...
Autores principales: | Riva, Nicoletta, Ageno, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938617/ https://www.ncbi.nlm.nih.gov/pubmed/33733025 http://dx.doi.org/10.1002/rth2.12480 |
Ejemplares similares
-
Reproductive issues in women on direct oral anticoagulants
por: Beyer‐Westendorf, Jan, et al.
Publicado: (2021) -
Considerations for use of direct oral anticoagulants in arterial disease
por: Siegal, Deborah M., et al.
Publicado: (2021) -
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
por: Mavromanoli, Anna C., et al.
Publicado: (2021) -
Visualizing thrombosis to improve thrombus resolution
por: Weisel, John W., et al.
Publicado: (2021) -
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy
por: Singh, Pradeep K., et al.
Publicado: (2021)